Inflamatory bowel disease
Conditions
Interventions
Cases group:None
Sponsors
Southern Medical University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign an informed consent form. 2. Age >=18 (in principle, not subject to self-modification). 3. Patients diagnosed with inflammatory bowel disease based on the internationally recognized Lennard-Jones standard.
Exclusion criteria
Exclusion criteria: 1. Have systemic diseases involving other organs, including severe diseases of important organs such as the heart, lungs, kidneys, immune-mediated disorders, metabolic diseases (e.g., diabetes, thyroid disorders), or malignant tumors. 2. Tested positive for antibodies against hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis during the screening period. 3. Significant laboratory abnormalities, as determined by the investigator, that may compromise patient safety or prevent completion of the clinical study: 1) Renal function: creatinine >1.5 times the upper limit of normal (ULN);2) Chronic liver disease and/or liver dysfunction: defined as AST >=1.5 times the upper limit of normal (ULN), and/or ALT >= 1.5 times the ULN, and/or total bilirubin >= 1.5 times the ULN. 4. Have other psychiatric disorders, excluding depression or anxiety disorders. 5. Have a history of substance abuse or alcohol abuse. 6. Pregnant or breastfeeding women. 7. Have severe psychological or behavioral issues that prevent cooperation with the study process or may interfere with the study. 8. Have participated in any clinical trial within the 3 months prior to signing the informed consent form. 9. The investigator deems the participant unsuitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal microbiota of patients with inflammatory bowel disease before and after treatment.;Fecal microbiota metabolites of patients with inflammatory bowel disease before and after treatment.;Plasma metabolites of patients with inflammatory bowel disease before and after treatment.;Intestine tissue transcriptome of patients with inflammatory bowel disease before and after treatment.; | — |
Countries
China
Contacts
Public ContactYe Chen
Southern Medical University Shenzhen Hospital
Outcome results
None listed